Proxygen & EPFL Team Up for AI Glue Discovery
Proxygen, a leader in molecular glue degrader discovery and development, has partnered with the Swiss Federal Institute of Technology...
AI Drug Discovery AstraZeneca BIO-Europe Spring 2026 biopharma M&A biopharma strategy biotech funding biotech strategy business development cancer immunotherapy China Biotech CNS Pipeline Strategy competitive intelligence Disease-Modifying Therapy Drug Pricing Strategy eClinical Tech News Eli Lilly Emerging Markets FDA Approval FDA Priority Review HER2 Oncology immuno-oncology immunology licensing deals Lifecycle Management Market Access Medtronic MSS colorectal cancer Novo Nordisk Obesity/GLP-1 Obesity Drug Market Obesity Market Oncology Pipeline Patent Cliff Priority Review Voucher pulmonary hypertension Rare Disease Regeneron respiratory biologics Roche Sanofi series A funding Teva Pharmaceuticals Type 1 Diabetes Type 2 Diabetes venture capital
No videos found.
Proxygen, a leader in molecular glue degrader discovery and development, has partnered with the Swiss Federal Institute of Technology...
PharmaTher Holdings Ltd. is aggressively pursuing a dual-pronged strategy centered around its recently FDA-approved ketamine product, KETARxâ„¢. The company...
CDT Equity Inc. has identified a new therapeutic indication for its lead program, AZD1656, based on promising pre-clinical data...
Odyssey Health, a technology and asset acquisition company, is advancing the development of its patented Save a Life (SAL)...
Zenas Biopharma, a clinical-stage biotech focused on autoimmune diseases, has announced its participation in three major investor conferences in...
In 2023, more than 300 children died across multiple countries—Gambia, Uzbekistan, and Cameroon—after taking contaminated cough syrup. The syrups...
Rakovina Therapeutics’ Chief Scientific Officer, Dr. Mads Daugaard, presented at the 13th Tuscany Retreat on Cancer Research and Apoptosis,...
PathAI expands FDA clearance for its AI-powered digital pathology image management system, AISight® DX, to include Roche’s Ventana DP...
Amarin Corporation is showcasing new data on icosapent ethyl (IPE), branded as Vascepa/Vazkepa, at the European Society of Cardiology...
Collegium Pharmaceutical is leveraging the upcoming PAINWeek 2025 conference to showcase a significant body of real-world data (RWD) supporting...
